The poly ADP ribose polymerase (PARP) inhibitors, such as AstraZeneca’s Lynparza, GSK’s Zejula, and Clovis Oncology’s Rubraca, have revolutionized the therapeutic landscape of platinum-sensitive ovarian cancer, where platinum-based regimens used to be the standard of care. Although substantial improvements have been made with the FDA’s 2019 approval of Lynparza for first-line maintenance therapy in advanced ovarian cancer, opportunity exists to develop more effective therapies for platinum-sensitive disease, while optimal sequencing of these therapies remains an unmet need.
- What are the treatment drivers and goals in surveyed medical oncologists’ prescribing decisions? What are the hidden opportunities that developers could leverage?
- How do current therapies, such as the PARP inhibitors, perform on key clinical attributes for this patient population?
- What are the greatest areas of unmet need and most attractive opportunities for platinum-sensitive ovarian cancer?
- What trade-offs are surveyed oncologists willing to make across key drug attributes and price when considering hypothetical target product profiles?
Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 62 U.S. and 30 European medical oncologists fielded in June 2020
Key companies: AstraZeneca, GSK, Clovis Oncology
Key drugs: Lynparza, Zejula, Rubraca
- Ovarian Cancer - Unmet Need - Detailed, Expanded Analysis (US/EU)
Author(s): Laura Vinuesa, DVM, MSc
Laura Vinuesa, DVM, M.Sc., is a Senior Business Insights Analyst in the Oncology Division at Decision Resources Group, with expertise in thyroid carcinoma and bladder cancer. Previously, Dr. Vinuesa was an EU Market Access Analyst in the Global Market Access Insights Team at Decision Resources Group. She has expertise in market access, pricing and reimbursement, health technology assessment, and health policy.
Prior to joining Decision Resources, she worked as Market Access & Institutional Relations Analyst at Pfizer in Spain, providing support for the successful market launch of drugs for different areas: cardiovascular, oncology, mental disorder and rare disease. She is a Doctor of Veterinary Medicine from the Complutense University of Madrid, and holds a M.Sc. in Clinical Research and Pharmaceutical Medicine from EPHOS - School of PharmaStudies.